secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025248
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics appoints Tobin Schilke as CFO effective Feb 28, 2025
--------------------------------------------------------------

- Tobin Schilke appointed CFO effective February 28, 2025, succeeding Marc Wilson.
- Schilke was previously CFO at Revance Therapeutics (2018-2025) and Achaogen.
- Base salary $540,000; target bonus 40% of salary; inducement grant of 52,000 RSUs and option for 80,000 shares.
- Marc Wilson's departure was previously announced in August 2024 for personal reasons.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025025248/0000950170-25-025248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025025248/crnx-20250221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer